Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma.

Abstract

A woman with a prolactinoma is usually infertile. Dopamine agonists usually restore ovulation and fertility and such treatment generally is preferred over transsphenoidal surgery because of higher efficacy and safety. Cabergoline is usually preferred over bromocriptine because of its better efficacy with fewer adverse effects. Either drug increases the rates of spontaneous abortions, preterm deliveries, multiple births, or congenital malformations over what may be expected. However, the number of pregnancies reporting such experience is about sevenfold greater for bromocriptine. Tumor growth causing significant symptoms and requiring intervention has been reported to occur in 2.4% of those with microadenomas, 21% in those with macroadenomas without prior surgery or irradiation, and 4.7% of those with macroadenomas with prior surgery or irradiation. Visual fields should be assessed periodically during gestation in women with macroadenomas. If significant tumor growth occurs, most patients respond well to reinstitution of the dopamine agonist. Delivery of the baby and placenta can also be considered if the pregnancy is sufficiently advanced. Transsphenoidal debulking of the tumor is rarely necessary.

• Authors: Mark E Molitch
• Journal: European journal of endocrinology (Eur J Endocrinol) Vol. 172 Issue 5 Pg. R205-13 (May 2015) ISSN: 1479-683X [Electronic] England
• PMID: 25805896 (Publication Type: Journal Article, Review)
• Copyright: © 2015 European Society of Endocrinology.

Chemical References

• Prolactin

Topics

• Adult
• Disease Management
• Female
• Fertility
• Humans
• Infant, Newborn
• Pituitary Neoplasms (metabolism, therapy)
• Pregnancy
• Pregnancy Complications, Neoplastic (metabolism, therapy)
• Prolactin (metabolism)
• Prolactinoma (metabolism, therapy)